“…To confirm IRF overexpression was not working by compensatory induction of IFNg/l, we treated the same cells with the Jak inhibitor ruxolitinib. Control and IFN-a3-stimulated cells showed a similar absence of IRG-induction profiles, as measured by a previously described nanostring panel (Irving et al, 2020), whereas ruxolitinib-treated cells with IFNa3 showed a slight increase, possibly indicating a degree of interference from IFNAR1 binding in the absence of IFNAR2. Fitting with the idea of Jak-STAT-signaling-independent, direct/indirect IRFdependent induction, ruxolitinib actually enhanced IRF-overexpression-induced IRG induction, particularly with genes such Cell Reports 33, 108345, November 3, 2020 5 Article ll OPEN ACCESS as XAF1, ZBP1, TLR6, RTP4, OASL, NLRC5, MX2, IFIT2/3, CXCL10, CIITA, and APOBEC3G (Figure S2I).…”